CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled
Drug / intervention
theophylline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05947643
NCT05947643Phase 2Completed
CompareCT.gov

Smell in COVID-19 and Efficacy of Nasal Theophylline 3

Washington University School of Medicine·interventional·Posted Jul 17, 2023·Updated Aug 20, 2025

In Brief

A Phase 2 clinical trial evaluating theophylline and Placebo for COVID-19. Completed, enrolled 77 participants across 1 site.

Detailed Summary

The purpose of this Phase II trial is to test the effectiveness of intranasal theophylline irrigations for the treatment of COVID-19 related smell dysfunction. The investigators will compare the effect of theophylline nasal rinses versus placebo nasal rinses on smell symptoms. Participants will be asked to rinse their nose with a medication or placebo capsule dissolved in saltwater twice daily for 12 weeks and fill out surveys about smell before, during, and at the end of treatment. This study will also be used to describe adverse effects related to intranasal theophylline irrigation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJul 17, 2023
Enrollment StartNov 22, 2022
Primary CompletionApr 24, 2025
Study CompletionAug 4, 2025
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 3.0 years ago

Interventions

theophyllinedrug

capsules dissolved in intranasal irrigation

Placebodrug

identical-appearing lactose capsules dissolved in intranasal irrigation